Drugs / CD19x22 CAR T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05098613 | Dec 2021 → Dec 2026 expected | central nervous system non-hodgkin lymphoma, mantle cell lymphoma | University of Colorado, Denver | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19x22 CAR T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05098613 ↗ |
| Known as | CD19x22 CART | “Lymphodepleting chemotherapy followed by CD19x22 CART Infusion starting at dose level 2.” NCT05098613 ↗ |
| Modality | Cell therapy | “anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells” NCT05098613 ↗ |
| Target | CD19 | “anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells” NCT05098613 ↗ |
| Target | CD22 | “anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells” NCT05098613 ↗ |